Not yet recruiting
Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence
NCT06958484
- Conditions
- Adenocarcinoma, Adjuvant Treatment, Carcinoma, +10 more
- Locations
-
Not specified